Immunic to showcase phase 2 long-term MS disability data at MSToronto2026

key takeaway, um, is that positive disability trends that we had observed in the double blind, the main treatment period of the caliper study, were maintained over a longer term followup.

Hello, you're watching Proactive on joins by Eric Lundgren, the CEO of Munich. Eric, very good to speak with you. Uh, you're headed to the world's largest MS meeting this week. What makes this year's MST Toronto 2026 the 10th joint Arumrum meeting feel different from the others you've attended over the years.

Well, first of all, good morning Stephen and thanks for the time. Um, well, I mean the most obvious one for me personally is it's my firstrum Congress um as the CEO of Imunic. So that really makes it feel different and special for me right off right off the the jump. So, um, and I I think for the company, it'll be our largest MS Congress presence that we've had really to date in the history of the company. We're going to have our own booth, we're going to have four accepted poster presentations, we're going to have an industry showcase. So we have a lot of activities going on and in some ways it's it's a real testament to the company really stepping further into this next phase of the company's development, which is moving from development to preparing for commercialization. Um, I'd just say among the posters that we have uh that we'll be presenting we're we're going to be showing up with some really exciting new long-term data from our phase two caliper uh study, which is a study conducted in progressive multiple sclerosis. Um, and then this is going to really give us an opportunity to engage with the MS community around the findings from that study from the open label extension. So, um and of course, in addition to the data, there's just the conversations, the connections, the relationships. Um that's always been and and remains some of the most useful elements of of a Congress such as such as therum meeting.

Eric, as you said, Munich will be presenting four abstracts in Toronto, two paper posters and two e- posters with the long-term caliper open label extension data being a key highlight. What do these new findings tell us aboutmus calcium potential in progressive MS?

Well, you know, I think I think the key takeaway, um is that positive disability trends that we had observed in the double blind, the main treatment period of the caliper study were maintained over a longer term followup, which is of vital importance, right? So um, the analysis that we conducted uh in the OLE included 24 week confirmed disability worsening uh, and 24 week confirmed disability improvement, which is extraordinarily important to people who are living with MS. Is that that idea of the the potential for improvement. Um, and these show favorable long-term benefits of being on beautifulmas calcium. So, um, you know, it's important to note as well that these trends were seen across various subgroups and sustained over the period of the of of followup in the study. So we're really encouraged um by this. We're encouraged by the high treatment persistence rate in the OLE alone, just how many people chose to stay in and and stay on. Um that's always a really good um sign. Um with having that low discontinuation rate uh and the tolerability profile has been consistent with the prior experiences. So taking together, I think these all add to a growing body of evidence that um support beautiful calcium's differentiated profile in in both uh uh relaxing as well as progressive forms of of multiple sclerosis.

What about the three other posters Eric?

Yeah, so in addition to the caliper open label poster that we just discussed, um, we're going to be presenting further insights on Nur1 and Nur1 mediated neural survival, which is really critical to beautiful calcium's um mechanistic um differentiation. Um, we'll be looking at Epstein bar virus related immune activity, um, and cognition. Um, which is a real emergent emerging hot topic in the field of MS. Um, and then a novel we'll we'll be really outlining a novel disability measurement. So all of these things taken together, again, they they kind of further deepen our understanding of calcium's potential um, to address both inflammatory disease activity as well as um disability progression and MS. So, you know, I'd say our four posters um at therum Congress this year, um add to the growing clinical and mechanistic evidence supporting um our profile across the whole spectrum of MS.

as the MS field increasingly focuses on disability progression, how do you see contributing to that discussion through the data you're presenting in Toronto?

Well, you know, Stephen, first first and foremost, I think disability progression is is really the central um and most pressing unmet need in MS treatment today, right? So, um, it really is the major focus of the field and I think beautiful calcium is is really contributing to the field's understanding of what can be done there. So relapses are are are are are pretty well controlled with the therapies on the market, but when you listen to patients and you listen to the physicians who dedicate their career to treating those patients, they really need more than relapse control. And and so they're looking for therapies that they're going to help them preserve function and ultimately their everyday, you know, independence over over a long period of time. Um and that's one of the reasons that I am extremely excited about the long-term disability outcomes that we already uh mentioned here in this discussion, uh that we're seeing from the caliper open label extension withmus calcium. And we think our our data are going to continue to to contribute to this growing discussion, to the sort of emerging scientific trends, uh and ultimately driving outcomes that matter to patients.

Eric, what are you most looking forward to when you get to Toronto?

Um, you know, I think it's it's it's really hearing the different perspectives, it's getting smarter on the emerging data and trends across across the MS um research landscape, of course. Uh it's meeting with clinicians, researchers, partners from across the whole spectrum of the community and there'll be a lot of old old familiar faces for me, but but hopefully some new ones as well, meeting meeting new new new collaborators. Um, and really it's learning. I mean it's a chance to learn. I think you want to have a uh a learner's mindset when you go into these meetings, um and just sort of soak on all of the incredible research and science going on across um the multiple sclerosis field to advanced care for patients. So, um so I think it's really, you know, doing all those things while raising the awareness of c and raising the awareness ofmus calcium um as we pivot into this new phase for us. So a lot of work to get done this week in Toronto, Stephen.

Well, I hope it all goes very well for you. I hope you'll keep us updated with your progress there. Thank you so much and thanks for the time.

That's Eric Lundgren, the CEO of Imunic.